Sivik Global Healthcare LLC Acquires New Position in BioNTech SE (NASDAQ:BNTX)

Sivik Global Healthcare LLC bought a new position in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 15,000 shares of the company’s stock, valued at approximately $1,709,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fred Alger Management LLC bought a new position in BioNTech during the 3rd quarter valued at about $59,485,000. Baillie Gifford & Co. raised its holdings in shares of BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in BioNTech by 63.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after purchasing an additional 7,340 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in BioNTech by 123.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock worth $15,919,000 after purchasing an additional 74,119 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after purchasing an additional 33,375 shares during the period. Institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BNTX. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and upped their price target for the company from $90.00 to $137.00 in a research report on Friday, November 8th. Berenberg Bank began coverage on shares of BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price for the company. Wells Fargo & Company began coverage on shares of BioNTech in a research note on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. TD Cowen cut their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus target price of $142.72.

BioNTech Stock Performance

NASDAQ BNTX opened at $121.79 on Thursday. The business’s 50 day moving average price is $116.88 and its 200-day moving average price is $106.67. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a market cap of $29.20 billion, a P/E ratio of -58.07 and a beta of 0.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the prior year, the firm posted $0.73 earnings per share. The company’s quarterly revenue was up 38.9% on a year-over-year basis. Sell-side analysts predict that BioNTech SE will post -3.77 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.